Clinical trials: Bladder, Overactive
Urinary Incontinence, Urinary Bladder, Overactive
516-BOTOX Urinary Incontinence Detrusor
The specific aim of this study is to evaluate the safety and efficacy of each of 2 dosages of BOTOX® (200 U or 300 U) compared to placebo injected into the detrusor for the treatment of urinary incontinence caused by neurogenic…
- Trial name
- NCT00850733
- Sponsor
- Veterans Medical Research Foundation
Overactive Bladder
Study of ONO-8539 in Patients With Overactive Bladder
The objective of this study is to investigate efficacy, safety and tolerability of ONO-8539 in patients with overactive bladder.
- Trial name
- NCT00876421
- Testing
- Tolterodine, ONO-8539
- Where
- 50 sites in Czechia, Germany and 7 more
- Volunteers
- 435 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Overactive Bladder
Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder
To evaluate the efficacy and safety after 12 weeks oral administration of Imidafenacin 0.1mg b.i.d versus Fesoterodine 4mg once daily for the urge incontinence and/or increased urinary frequency associated with urgency as may…
- Trial name
- NCT01578304
- Testing
- Imidafenacin, Fesoterodine
- Where
- South Korea
- Volunteers
- 207 people
- Sponsor
- LG Life Sciences
Overactive Bladder (OAB)
Tensi+ for Treating Overactive Bladder
The purpose of the study is to evaluate the safety and effectiveness of the Tensi+ device using Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) for treating patients suffering from OAB symptoms urinary frequency…
- Trial name
- NCT07300904
- Testing
- Tensi+
- Where
- 3 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Stimuli Technology
Overactive Bladder
Instillation of Botox in the Bladder in Women With Overactive Bladder (OAB)
Instillation treatment with onabotulinumtoxin A (BOTOX®) in the urinary bladder
- Trial name
- NCT02735499
- Testing
- onabotulinum toxin A
- Where
- Norway
- Volunteers
- 14 people
- Sponsor
- The Hospital of Vestfold
Overactive Bladder Syndrome
The Effect of Position on Urge Sensation in Volunteers and in Patients With Overactive Bladder Syndrome
Importance of the problem OAB is a common health problem. Milsom et al. [1] randomly selected a population from six European countries.
- Trial name
- NCT00821314
- Where
- Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Overactive Bladder
The Efficacy of Botulinum Toxin in OVERACTIVE Bladder
To assess the efficacy of botulinum toxin injection in overactive bladder.
- Trial name
- NCT03888001
- Where
- Egypt
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Assiut University
Overactive Bladder
Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder
This study will help determine if behavior modification performed in conjunction with oral Vesicare anticholinergic therapy is more effective for treating overactive bladder symptoms than oral Vesicare anticholinergic therapy…
- Trial name
- NCT00821184
- Testing
- Vesicare (solifenacin), Vesicare (solifenacin) plus behavioral modification
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Lahey Clinic
Urinary Urge Incontinence (UUI), Urinary Frequency (UF)
Aquarius Pilot Study to Evaluate the New Axonics Trial System
Evaluation of the new Axonics External Trial System (ETS-02) in patients with overactive bladder (OAB) and/or fecal incontinence (FI).
- Conditions
- Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI), Overactive Bladder (OAB)
- Trial name
- NCT07335484
- Testing
- Axonics External Trial System (ETS)
- Where
- 5 sites in United States, Australia
- Volunteers
- 75 people
- Sponsor
- Axonics, Inc.
Urinary Retention, Urinary Urge Incontinence
Axonics SacRal NeuromodulaTIon System RegisTRY Study
To assess the post-market clinical outcomes with use of the Axonics Sacral Neuromodulation System(s).
- Conditions
- Urinary Retention, Urinary Urge Incontinence, Urgency-Frequency, Fecal Incontinence
- Trial name
- ARTISTRY (NCT05064384)
- Where
- 27 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Axonics, Inc.
Overactive Bladder
Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.
To assess the long term safety, tolerability and efficacy of fesoterodine in patients with OAB.
- Trial name
- NCT00658684
- Testing
- fesoterodine fumarate
- Where
- 12 sites in Japan
- Volunteers
- 153 people
- Sponsor
- Pfizer
Overactive Bladder
At-Home Transcutaneous Tibial Nerve Stimulation for Overactive Bladder in Rural Women
This study contains a mixed-methods design consisting of a single-arm, interventional study and prospective patient interviews evaluating a novel self-implemented at-home Transcutaneous Tibial Nerve Stimulation (TTNS) treatment…
- Trial name
- NCT07178314
- Testing
- Transcutaneous Tibial Nerve Stimulation (TTNS)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Oregon Health and Science University
Treatment of Overactive Bladder
A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects
This bioequivalence (BE) study is to satisfy FDA regulatory requirements for extended releases drug product transfer from Zwickau, Germany to Vega Baja, Puerto-Rico.
- Trial name
- NCT00902681
- Testing
- Fesoterodine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overactive Bladder
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.
- Trial name
- NCT02656173
- Testing
- Mirabegron, Tamsulosin
- Where
- 58 sites in Japan, South Korea
- Volunteers
- 568 people
- Sponsor
- Astellas Pharma Inc
Prostate Adenocarcinoma
A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy
The investigators will assess the incidence of Overactive Bladder/Detrusor Overactivity (OAB/DO) post-operatively in patients post robotic assisted radical prostatectomy (RARP) and to investigate whether fesoterodine will alter…
- Trial name
- NCT01661166
- Testing
- Fesoterodine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Overactive Bladder
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
The main hypothesis of this study is that magnetic neuromodulation can be used to correct bladder overactivity. The investigators assume that the transvertebral magnetic stimulation can improve both the subjective state of…
- Trial name
- NCT04578899
- Testing
- Transvertebral magnetic stimulation
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Joint-Stock Company North-West Center for Evidence-Based Medicine, Russian Federation
Urinary Bladder, Overactive
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of YM178 against placebo and tolterodine to treat patients with symptoms of over active bladder.
- Trial name
- Blossom (NCT01604928)
- Testing
- YM178, tolterodine
- Where
- 30 sites in Belgium, Czechia and 4 more
- Volunteers
- 260 people
- Sponsor
- Astellas Pharma Europe B.V.
Overactive Bladder Syndrome, Urinary Urge Incontinence
Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial
Overactive bladder is a common condition that causes sudden urges to urinate, frequent urination, night-time urination, and sometimes leakage of urine.
- Conditions
- Overactive Bladder Syndrome, Urinary Urge Incontinence, Detrusor Overactivity
- Trial name
- NCT07184307
- Testing
- Platelet-Rich Plasma, Intravesical Botulinum Toxin Injection
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Benha University
Overactive Bladder
The Urinary Microbiome in Patients Receiving Intradetrusor Botox Injections
An altered urinary microbiome (UM) may explain the symptoms in overactive bladder (OAB) patients who were previously considered to have "idiopathic" OAB.
- Trial name
- NCT04479709
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- MetroHealth Medical Center
Overactive Bladder With Urge Urinary Incontinence
URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
This study will evaluate the efficacy, safety, and tolerability of a single dose of URO-902 24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with placebo, in participants with overactive bladder…
- Trial name
- NCT04211831
- Testing
- URO-902
- Where
- 20 sites in United States
- Volunteers
- 80 people
- Sponsor
- Urovant Sciences GmbH